Interplay of Th1 and Th17 cells in murine models of malignant pleural effusion

American Journal of Respiratory and Critical Care Medicine

Volumn 189, Issue 6, 2014, Pages 697-706

  Lin, Hua ^a   Tong, Zhao Hui ^b   Xu, Qian Qian ^a   Wu, Xiu Zhi ^a   Wang, Xiao Juan ^b   Jin, Xiao Guang ^b   Ma, Wan Li ^a   Cheng, Xiang ^a   Zhou, Qiong ^a   Shi, Huan Zhong ^a,b,c  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Lung cancer; Malignant pleural effusion; Th1 cells; Th17 cells

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17; STAT3 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; CELL COUNT; CELL DIFFERENTIATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; IMMUNOREGULATION; IN VITRO STUDY; MALIGNANT PLEURA EFFUSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; TH1 CELL; TH17 CELL; WILD TYPE;

ANIMALS; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; CELL DIFFERENTIATION; FLOW CYTOMETRY; INTERFERON-GAMMA; INTERLEUKIN-17; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PLEURAL EFFUSION, MALIGNANT; REAL-TIME POLYMERASE CHAIN REACTION; TH1 CELLS; TH17 CELLS;

EID: 84896504644     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201310-1776OC     Document Type: Article

References (38)

1. Light RW. Clinical practice: Pleural effusion. N Engl J Med 2002;346: 1971-1977.
2. Sugiura S, Ando Y, Minami H, Ando M, Sakai S, Shimokata K. Prognostic value of pleural effusion in patients with non-small cell lung cancer. Clin Cancer Res 1997;3:47-50.
3. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-714.
4. Stathopoulos GT, Kalomenidis I. Malignant pleural effusion: Tumor-host interactions unleashed. Am J Respir Crit Care Med 2012;186:487-492.
5. Lucivero G, Pierucci G, Bonomo L. Lymphocyte subsets in peripheral blood and pleural fluid. Eur Respir J 1988;1:337-340.
6. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009;361:888-898.
7. Zou W, Restifo NPT. T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 2010;10:248-256.
8. Ye J, Livergood RS, Peng G. The role and regulation of human Th17 cells in tumor immunity. Am J Pathol 2013;182:10-20.
9. Gocke AR, Cravens PD, Ben LH, Hussain RZ, Northrop SC, Racke MK, Lovett-Racke AE. T-bet regulates the fate of Th1 and Th17 lymphocytes in autoimmunity. J Immunol 2007;178: 1341-1348.
10. Yang Y, Weiner J, Liu Y, Smith AJ, Huss DJ, Winger R, Peng H, Cravens PD, Racke MK, Lovett-Racke AE. T-bet is essential for encephalitogenicity of both Th1 and Th17 cells. J Exp Med 2009; 206:1549-1564.
11. Ye ZJ, Zhou Q, Gu YY, Qin SM, Ma WL, Xin JB, Tao XN, Shi HZ. Generation and differentiation of IL-17-producing CD41 T cells in malignant pleural effusion. J Immunol 2010;185: 6348-6354.
12. Nakae S, Komiyama Y, Nambu A, Sudo K, Iwase M, Homma I, Sekikawa K, Asano M, Iwakura Y. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 2002;17: 375-387.
13. Stathopoulos GT, Zhu Z, Everhart MB, Kalomenidis I, Lawson WE, Bilaceroglu S, Peterson TE, Mitchell D, Yull FE, Light RW, et al. Nuclear factor-kappaB affects tumor progression in a mouse model of malignant pleural effusion. Am J Respir Cell Mol Biol 2006;34: 142-150.
14. Stathopoulos GT, Sherrill TP, Karabela SP, Goleniewska K, Kalomenidis I, Roussos C, Fingleton B, Yull FE, Peebles RS Jr, Blackwell TS. Host-derived interleukin-5 promotes adenocarcinomainduced malignant pleural effusion. Am J Respir Crit Care Med 2010; 182:1273-1281.
15. Sahn SA. Pleural diseases related to metastatic malignancies. Eur Respir J 1997;10:1907-1913.
16. Kryczek I, Wei S, Zou L, Altuwaijri S, Szeliga W, Kolls J, Chang A, Zou W. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 2007; 178:6730-6733.
17. Miyahara Y, Odunsi K, Chen W, Peng G, Matsuzaki J, Wang RF. Generation and regulation of human CD41 IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci USA 2008;105: 15505-15510.
18. Sfanos KS, Bruno TC, Maris CH, Xu L, Thoburn CJ, DeMarzo AM, Meeker AK, Isaacs WB, Drake CG. Phenotypic analysis of prostateinfiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res 2008;14:3254-3261.
19. Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L, Wu C, Li SP, Zheng L. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 2009;50: 980-989.
20. Ye ZJ, Zhou Q, Zhang JC, Li X, Wu C, Qin SM, Xin JB, Shi HZ. CD391 regulatory T cells suppress generation and differentiation of Th17 cells in human malignant pleural effusion via a LAP-dependent mechanism. Respir Res 2011;12:77.
21. Benchetrit F, Ciree A, Vives V, Warnier G, Gey A, Sautes-Fridman C, Fossiez F, Haicheur N, Fridman WH, Tartour E. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 2002;99:2114-2121.
22. Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, Paulos CM, Palmer DC, Touloukian CE, Ptak K, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008;112:362-373.
23. Gnerlich JL, Mitchem JB, Weir JS, Sankpal NV, Kashiwagi H, Belt BA, Porembka MR, Herndon JM, Eberlein TJ, Goedegebuure P, et al. Induction of Th17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer. J Immunol 2010; 185:4063-4071.
24. Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, Hwu P, Restifo NP, Overwijk WW, Dong C. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 2009;31:787-798.
25. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, Robbins PD, Tahara H, Lotze MT. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003;101:2620-2627.
26. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 2009;206:1457-1464.
27. Muranski P, Restifo NP. Adoptive immunotherapy of cancer using CD4(1) T cells. Curr Opin Immunol 2009;21:200-208.
28. Haabeth OA, Lorvik KB, Hammarström C, Donaldson IM, Haraldsen G, Bogen B, Corthay A. Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun 2011;2:240.
29. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH, et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009;114:1141-1149.
30. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000;100:655-669.
31. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ, Littman DR. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-171 T helper cells. Cell 2006;126:1121-1133.
32. Adamson AS, Collins K, Laurence A, O'Shea JJ. The Current STATus of lymphocyte signaling: New roles for old players. Curr Opin Immunol 2009;21:161-166.
33. O'Shea JJ, Lahesmaa R, Vahedi G, Laurence A, Kanno Y. Genomic views of STAT function in CD41 T helper cell differentiation. Nat Rev Immunol 2011;11:239-250.
34. Hong F, Jaruga B, Kim WH, Radaeva S, El-Assal ON, Tian Z, Nguyen VA, Gao B. Opposing roles of STAT1 and STAT3 in T cell-mediated hepatitis: Regulation by SOCS. J Clin Invest 2002;110:1503-1513.
35. Chen Z, Laurence A, Kanno Y, Pacher-Zavisin M, Zhu BM, Tato C, Yoshimura A, Hennighausen L, O'Shea JJ. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc Natl Acad Sci USA 2006;103:8137-8142.
36. Harris TJ, Grosso JF, Yen HR, Xin H, Kortylewski M, Albesiano E, Hipkiss EL, Getnet D, Goldberg MV, Maris CH, et al. Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol 2007;179:4313-4317.
37. Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunol Rev 2008;223:87-113.
38. Martin F, Apetoh L, Ghiringhelli F. Controversies on the role of Th17 in cancer: A TGF-b-dependent immunosuppressive activity? Trends Mol Med 2012;18:742-749.